D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study

Olfactory dysfunction is frequently observed in patients with chronic rhinosinusitis with nasal polyp (CRSwNP), and has a significant impact on their quality of life. Although dupilumab has shown favorable outcomes, real-world data using Korean-validated olfactory tests remain limited. 

A prospective observational study was conducted at a single tertiary hospital in patients with uncontrolled CRSwNP. Ten patients were treated with dupilumab every 2 weeks for 6 months, and outcomes were assessed using YSK olfactory function (YOF), olfactory visual analogical scale (VAS), and sino-nasal outcome test (SNOT-22). 

Treatment with dupilumab resulted in statistically significant improvements in YOF scores (0.2 ± 0.63 vs.21.85 ± 6.38; p = 0.005), olfactory VAS (0.3 ± 0.95 vs. 4.8± 3.46; p = 0.012), and SNOT-22 scores (42.6 ± 22.86 vs. 21.2 ± 18.03; p = 0.005) at 6 months compared with baseline. All three olfactory domains (threshold, discrimination and identification) of YOF also showed improvement. At baseline, all patients had anosmia; at the end of treatment, 2 patients remained anosmic, 1 had hyposmia, and 7 had normal olfactory function. Dupilumab also decreased nasal polyp score (3.7±0.82 vs. 1.0±1.49; p = 0.007). A significant decreases of serum total IgE and fractional exhaled nitric oxide levels were observed. Additionally, self-reported anxiety and depression improved.

Treatment with dupilumab resulted in statistically significant improvements in YOF scores (0.2 ± 0.63 vs.21.85 ± 6.38; p = 0.005), olfactory VAS (0.3 ± 0.95 vs. 4.8± 3.46; p = 0.012), and SNOT-22 scores (42.6 ± 22.86 vs. 21.2 ± 18.03; p = 0.005) at 6 months compared with baseline. All three olfactory domains (threshold, discrimination and identification) of YOF also showed improvement. At baseline, all patients had anosmia; at the end of treatment, 2 patients remained anosmic, 1 had hyposmia, and 7 had normal olfactory function. Dupilumab also decreased nasal polyp score (3.7±0.82 vs. 1.0±1.49; p = 0.007). A significant decreases of serum total IgE and fractional exhaled nitric oxide levels were observed. Additionally, self-reported anxiety and depression improved.